Lazard Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Lazard Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12	Closed	-$1K	–	2553
2023 Q3	$1K	Hold	12	–	–	﹤0.01%	2244
2023 Q2	$1K	Hold	12	–	–	﹤0.01%	2271
2023 Q1	$1K	Hold	12	–	–	﹤0.01%	2267
2022 Q4	$1K	Hold	12	–	–	﹤0.01%	2353
2022 Q3	$0	Buy	12 +6	+100%	+$419	﹤0.01%	2635
2022 Q2	$0	Sell	6 -201	-97%	-$19K	﹤0.01%	2656
2022 Q1	$21K	Sell	207 -19,916	-99%	-$1.94M	﹤0.01%	2062
2021 Q4	$2.17M	Buy	20,123 +2,477	+14%	+$270K	﹤0.01%	922
2021 Q3	$1.93M	Buy	17,646 +17,236	+4,204%	+$1.79M	﹤0.01%	918
2021 Q2	$38K	Sell	410 -13,334	-97%	-$1.23M	﹤0.01%	1707
2021 Q1	$1.26M	Buy	+13,744	New	+$1.16M	﹤0.01%	867
2020 Q3	–	Sell	-969	Closed	-$53K	–	1814
2020 Q2	$53K	Sell	969 -2,042	-68%	-$87.4K	﹤0.01%	1216
2020 Q1	$89K	Buy	+3,011	New	+$102K	﹤0.01%	1023

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lazard Asset Management's HZNP Position: Q4 2023 in Review

Lazard Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 12 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in HZNP in Q1 2020 and held it in 13 quarters. The position peaked at $2.17M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Lazard Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Lazard Asset Management sold 12 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1K.
Lazard Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 13 quarters.
Lazard Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.17M in Q4 2021.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.